Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May;80(5-6):821–826. doi: 10.1038/sj.bjc.6690427

Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene

D S Liscia 1, R Morizio 1, T Venesio 1, C Palenzona 1, M Donadio 1, R Callahan 2
PMCID: PMC2362303  PMID: 10360661

Abstract

Several studies indicate that the short arm of chromosome 17 is one of the most frequently altered regions in sporadic breast carcinomas (45–60%). In the present report the 17p13.3-ter locus in tumour DNA of breast cancer patients, along with their matching normal lymphocyte DNA, have been mapped with four markers (D17S5, D17S379, ABR and D17S34), spanning nearly 3 cM of the telomer. Sixty-five of 143 heterozygous tumours had lost at least one of the markers at the minimum region of loss (45%). High levels of loss of these distal markers on 17p13.3 are independent of TP53 mutations and are associated with tumour cell proliferation. A follow-up period of over 7 years demonstrates that loss of these markers correlates both with disease-free (P = 0.004) and overall survival (P = 0.007). In addition we show that for disease-free survival the prognostic power of this genetic alteration is second only to axillary lymph node involvement (3.1 vs 6.3 relative risk), and is a better predictor than the mutational status of TP53 (1.6 relative risk). Our results are further evidence of the presence, within the region, of at least a second tumour suppressor gene distal to TP53, that might be targeted by deletions. © 1999 Cancer Research Campaign

Keywords: breast cancer, chromosome 17p13.3, LOH, survival

Full Text

The Full Text of this article is available as a PDF (143.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonadonna G., Valagussa P., Tancini G., Rossi A., Brambilla C., Zambetti M., Bignami P., Di Fronzo G., Silvestrini R. Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. NCI Monogr. 1986;(1):45–49. [PubMed] [Google Scholar]
  2. Carrozzo R., Ledbetter D. H. Dinucleotide repeat polymorphism mapping to the critical region for lissencephaly (17p13.3). Hum Mol Genet. 1993 May;2(5):615–615. doi: 10.1093/hmg/2.5.615. [DOI] [PubMed] [Google Scholar]
  3. Coles C., Thompson A. M., Elder P. A., Cohen B. B., Mackenzie I. M., Cranston G., Chetty U., Mackay J., Macdonald M., Nakamura Y. Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis. Lancet. 1990 Sep 29;336(8718):761–763. doi: 10.1016/0140-6736(90)93236-i. [DOI] [PubMed] [Google Scholar]
  4. Gudmundsson J., Johannesdottir G., Bergthorsson J. T., Arason A., Ingvarsson S., Egilsson V., Barkardottir R. B. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res. 1995 Nov 1;55(21):4830–4832. [PubMed] [Google Scholar]
  5. Heisterkamp N., Kaartinen V., van Soest S., Bokoch G. M., Groffen J. Human ABR encodes a protein with GAPrac activity and homology to the DBL nucleotide exchange factor domain. J Biol Chem. 1993 Aug 15;268(23):16903–16906. [PubMed] [Google Scholar]
  6. Isomura M., Tanigami A., Saito H., Harada Y., Katagiri T., Inazawa J., Ledbetter D. H., Nakamura Y. Detailed analysis of loss of heterozygosity on chromosome band 17p13 in breast carcinoma on the basis of a high-resolution physical map with 29 markers. Genes Chromosomes Cancer. 1994 Mar;9(3):173–179. doi: 10.1002/gcc.2870090305. [DOI] [PubMed] [Google Scholar]
  7. Knudson A. G., Jr Hereditary cancer, oncogenes, and antioncogenes. Cancer Res. 1985 Apr;45(4):1437–1443. [PubMed] [Google Scholar]
  8. Lancaster J. M., Wooster R., Mangion J., Phelan C. M., Cochran C., Gumbs C., Seal S., Barfoot R., Collins N., Bignell G. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet. 1996 Jun;13(2):238–240. doi: 10.1038/ng0696-238. [DOI] [PubMed] [Google Scholar]
  9. Lindblom A., Skoog L., Andersen T. I., Rotstein S., Nordenskjöld M., Larsson C. Four separate regions on chromosome 17 show loss of heterozygosity in familial breast carcinomas. Hum Genet. 1993 Mar;91(1):6–12. doi: 10.1007/BF00230213. [DOI] [PubMed] [Google Scholar]
  10. Mackay J., Steel C. M., Elder P. A., Forrest A. P., Evans H. J. Allele loss on short arm of chromosome 17 in breast cancers. Lancet. 1988 Dec 17;2(8625):1384–1385. doi: 10.1016/s0140-6736(88)90584-3. [DOI] [PubMed] [Google Scholar]
  11. Merlo G. R., Venesio T., Bernardi A., Cropp C. S., Diella F., Cappa A. P., Callahan R., Liscia D. S. Evidence for a second tumor suppressor gene on 17p linked to high S-phase index in primary human breast carcinomas. Cancer Genet Cytogenet. 1994 Sep;76(2):106–111. doi: 10.1016/0165-4608(94)90458-8. [DOI] [PubMed] [Google Scholar]
  12. Milner J., Medcalf E. A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell. 1991 May 31;65(5):765–774. doi: 10.1016/0092-8674(91)90384-b. [DOI] [PubMed] [Google Scholar]
  13. Mittra I., MacRae K. D. A meta-analysis of reported correlations between prognostic factors in breast cancer: does axillary lymph node metastasis represent biology or chronology? Eur J Cancer. 1991;27(12):1574–1583. doi: 10.1016/0277-5379(91)90418-d. [DOI] [PubMed] [Google Scholar]
  14. Morris C., Benjes S., Haataja L., Ledbetter D. H., Heisterkamp N., Groffen J. Spatial organization of ABR and CRK genes on human chromosome band 17p13.3. Oncogene. 1995 Mar 2;10(5):1009–1011. [PubMed] [Google Scholar]
  15. Nagai M. A., Pacheco M. M., Brentani M. M., Marques L. A., Brentani R. R., Ponder B. A., Mulligan L. M. Allelic loss on distal chromosome 17p is associated with poor prognosis in a group of Brazilian breast cancer patients. Br J Cancer. 1994 Apr;69(4):754–758. doi: 10.1038/bjc.1994.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Radford D. M., Fair K. L., Phillips N. J., Ritter J. H., Steinbrueck T., Holt M. S., Donis-Keller H. Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res. 1995 Aug 1;55(15):3399–3405. [PubMed] [Google Scholar]
  17. Sato T., Tanigami A., Yamakawa K., Akiyama F., Kasumi F., Sakamoto G., Nakamura Y. Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res. 1990 Nov 15;50(22):7184–7189. [PubMed] [Google Scholar]
  18. Schultz D. C., Vanderveer L., Berman D. B., Hamilton T. C., Wong A. J., Godwin A. K. Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res. 1996 May 1;56(9):1997–2002. [PubMed] [Google Scholar]
  19. Sidransky D., Tokino T., Helzlsouer K., Zehnbauer B., Rausch G., Shelton B., Prestigiacomo L., Vogelstein B., Davidson N. Inherited p53 gene mutations in breast cancer. Cancer Res. 1992 May 15;52(10):2984–2986. [PubMed] [Google Scholar]
  20. Sjögren S., Inganäs M., Norberg T., Lindgren A., Nordgren H., Holmberg L., Bergh J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996 Feb 21;88(3-4):173–182. doi: 10.1093/jnci/88.3-4.173. [DOI] [PubMed] [Google Scholar]
  21. Stack M., Jones D., White G., Liscia D. S., Venesio T., Casey G., Crichton D., Varley J., Mitchell E., Heighway J. Detailed mapping and loss of heterozygosity analysis suggests a suppressor locus involved in sporadic breast cancer within a distal region of chromosome band 17p13.3. Hum Mol Genet. 1995 Nov;4(11):2047–2055. doi: 10.1093/hmg/4.11.2047. [DOI] [PubMed] [Google Scholar]
  22. Theile M., Hartmann S., Scherthan H., Arnold W., Deppert W., Frege R., Glaab F., Haensch W., Scherneck S. Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes. Oncogene. 1995 Feb 2;10(3):439–447. [PubMed] [Google Scholar]
  23. Wales M. M., Biel M. A., el Deiry W., Nelkin B. D., Issa J. P., Cavenee W. K., Kuerbitz S. J., Baylin S. B. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med. 1995 Jun;1(6):570–577. doi: 10.1038/nm0695-570. [DOI] [PubMed] [Google Scholar]
  24. White G. R., Stack M., Santibáez-Koref M., Liscia D. S., Venesio T., Wang J. C., Helms C., Donis-Keller H., Betticher D. C., Altermatt H. J. High levels of loss at the 17p telomere suggest the close proximity of a tumour suppressor. Br J Cancer. 1996 Sep;74(6):863–870. doi: 10.1038/bjc.1996.449. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES